wonderful agenda for the #leiomysarcoma community in berlin🇩🇪 time to work on harmonized af lms care and future directions ⁦@ctosociety⁩

Discussing the reality of sarcoma patient care in Brazil during the SPAGN Annual Conference - @_CamposFernando https://t.co/QuVactBirS #Sarcoma #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #SPAGN

Patient advocacy plays a vital role in improving care for rare cancers in developing countries. Learn how the Desmoid Tumor Brazilian Association (DTBA) is tackling challenges like access to specialists and medications for patients in Brazil: https://t.co/VBxzlZH2ts #RareCancers

Special thanks to @CostaPhilippos and @_CamposFernando, one of our Editorial Review Board Members, for shedding light on the critical work of the Desmoid Tumor Brazilian Association in enhancing rare cancer care in Brazil

Through the lens of the Brazilian Desmoid Tumor Association, we highlight the crucial role of patient advocacy groups in advancing care for those with rare tumors/cancers in developing countries. @CostaPhilippos https://t.co/btTkkFmhpr

Together with Dr. Bernd Kasper, we explore the pharmacological characteristics of Nirogacestat, its current role in treating desmoid tumors, and future prospects. #DesmoidTumor #Sarcoma

Fantastic presentations today by @danhdtruong and @im_schaefer at ‘Next Frontiers to Cure Cancer’ by @acccancercenter. Enlightening insights on targeting differentiation errors in sarcomas and restoring cell cycle control in GISTs. #sarcomas # GISTS #accamargo

Wonderful evening with inspiring sarcoma friends at the @NLMSF Roundtable in Toronto this year! @DrLizConnolly @priyachudasama5 @saxotomy

🎬 It’s a wrap on two fantastic days of #LMS discussions and science with international colleagues! Thanks to @NLMSF for this yearly round table. Thanks to @GladdyLab and Albiruni Razak and the Toronto group for hosting us! Thanks to all speakers and participants!

It’s out! This guideline @JAMAOnc #desmoid reflects our multidisciplinary global collaboration, highlights new treatment strategies &importance of quality of life. Thanks Bernd Kasper, @alegronchi, pts, all. Current Management of Desmoid Tumors: A Review.

Yes!

An award that certainly comes with a lot of responsibility. Thank you very much, CTOS! Global outreach, global impact! #CTOS2023

First day at #CTOS was amazing. Had the privilege to bump into my Brazilian sarcoma colleagues! @PriscilaBCMD @PestanaRC @_CamposFernando

CTOS Webinar today discussing Alveolar Soft Part Sarcoma. Great presentations on the evolution of treatment, diagnosis, and current evidence-based management. @ctosociety

Vancouver (such a beautiful city!) is yellow now to receive CTOS 2022! I'm super excited for my first face-to-face CTOS meeting. #CTOS2022 @ctosociety

https://t.co/YcoDVZ7X66

Rare, often misdiagnosed, accounts for 1% of all adult cancers and 15 to 20% of childhood cancers. In 2022, an estimated 17,000 people will be diagnosed, and over 7,200 people will die, 42% of diagnosed cases. Read more here: https://t.co/J0CNeiLgTo #sarcomaawarenessmonth

Just chaired the session on H&N Sarcomas in the Next Frontiers to Cure Cancer @acccancercenter . No better way to finish the sarcoma agenda than with the great talk by @ManuPalmerini , and interesting case discussion with my colleagues from AC Camargo.

Great discussions on today’s Sarcoma Session from AC Camargo @acccancercenter Meeting “Next Frontiers to Cure Cancer”. @tomassoule @CelsoMello15 @vinodravi @salvoprovnz @DorianGarciaMD

Press release results - new drug for a rare sarcoma 👉🏼 Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors | BioSpace ⁦@JTrentMDPhD⁩ ⁦@APConley77⁩